Different Doses of Dexmedetomidine in External Oblique Intercostal Plane Block in Splenectomy

T

Tanta University

Status

Not yet enrolling

Conditions

External Oblique Intercostal Plane Block
Dexmedetomidine
Splenectomy

Treatments

Drug: Dexmedetomidine 1 μg/kg
Drug: Dexmedetomidine 0.5 μg/kg

Study type

Interventional

Funder types

Other

Identifiers

NCT06363578
36264PR604/3/24

Details and patient eligibility

About

The aim of this study is to compare the analgesic effects of different doses of dexmedetomidine as an adjuvant in external oblique intercostal plane block (EOIPB) in splenectomy.

Full description

External oblique intercostal plane block (EOIPB) was reported by Elsharkawy et al . It is a novel block, which has been described as an important modification of the fascial plane blocks that can consistently involve the upper lateral abdominal walls. In comparison to quadratus lumborum block (QLB) and erector spinae plane block (ESPB) , EOIPB has the benefit of being performed when the patient is supine. It also has an advantage over serratus intercostal plane block (SIPB) in that it produces greater analgesia throughout the midline of the abdomen. Dexmedetomidine is used for sedation in patients admitted to the intensive care unit (ICU). Dexmedetomidine is a selective alpha 2- adrenoceptor agonist possessing sedative, anxiolytic, and analgesic properties without the development of respiratory depression . Several studies have shown that dexmedetomidine has an anesthetic sparing effect, which has led to its use as a general adjuvant for prolonging peripheral nerve block duration.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years.
  • Both sexes.
  • American Society of Anesthesiology (ASA) physical status II-III.
  • Scheduled for splenectomy.

Exclusion criteria

  • Body mass index (BMI) ≥35 kg/m2
  • History of abdominal surgery.
  • Infection at the injection site.
  • Drug abuse.
  • Allergic reaction to local anesthetics.
  • Coagulation abnormalities.
  • Pregnancy.
  • Severe cardiovascular problems.
  • Diabetic neuropathy.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

50 participants in 2 patient groups

Group dexmedetomidine 0.5
Experimental group
Description:
Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg diluted in saline.
Treatment:
Drug: Dexmedetomidine 0.5 μg/kg
Group dexmedetomidine1
Experimental group
Description:
Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 1 μg/kg diluted in saline.
Treatment:
Drug: Dexmedetomidine 1 μg/kg

Trial contacts and locations

1

Loading...

Central trial contact

Mohammed S ElSharkawy, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems